Harrow Health, Inc.

NASDAQ:HROW

Drug Manufacturers - Specialty & Generic

Healthcare
$32.16 +0.29%

+$0.12 today

Market cap
$1.21B
Beta
0.28
P/E (TTM)
-104.7
EPS (TTM)
-$0.40
52W Low $28.54High $54.85

Volume 0.87M

Average 0.75M

HROW EBITDA Margin

EBITDA as a percentage of revenue.

Harrow Health, Inc.NASDAQ: HROW

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to -37.3%

EBITDA Margin was -37.3% in Q1 FY2026, down 23.3 pp from a year earlier. On a trailing-twelve-month basis it was 11.7%, up 3.4 pp year over year. Over 3 fiscal years it widened by 19.6 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 7 analysts of 14.2% for the fiscal year ending Dec 2026, down from 15.2% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-37.3%-60.2 pp QoQ
Last fiscal yearDec 2025
15.2%+4.1 pp YoY
LTMMar 2026
11.7%+3.4 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-23.3 pp-17.2 pp+6.2 pp
1 year+4.1 pp-1.0 pp-5.1 pp
3 years+19.6 pp+28.1 pp+8.5 pp
5 years+36.2 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
15.2%
Year-over-year change
+4.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How HROW compares with its peers on the latest reported figures

  • HROW's LTM Mar 2026 EBITDA Margin of 11.7% is the 2nd highest of the 7 companies compared; the peer median is -1971.1%.
  • Its year-over-year change of +3.4 pp is the 2nd highest of 6, against a peer median of -231.3 pp.
  • Over three fiscal years its change of +19.6 pp compares with a peer median of -183.6 pp.
HROW Competitors Peer median
EBITDA Margin for HROW and competitors
Company Period LTM level YoY 3-year change
BLCOBausch + Lomb CorporationLTM Jun 202613.9% +4.5 pp-5.4 pp
HROWHarrow Health, Inc.LTM Mar 202611.7% +3.4 pp+19.6 pp
TARSTarsus Pharmaceuticals, Inc.LTM Sep 2026-100.7% -80.8 pp+219.4 pp
OCULOcular Therapeutix, Inc.LTM Mar 2026-527.0% -231.3 pp-361.8 pp
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026-3415.1% -3156.5 pp-497.7 pp
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-18634.1% -28166.9 pp—
OCSOculis Holding AGLTM Mar 2026-18676.3% ——
KODKodiak Sciences Inc.FY2025— ——
TTRXTurn Therapeutics Inc.FY2025— ——
Peer median (excluding HROW) -1971.1%-231.3 pp-183.6 pp

Competitors are the stored peer set for HROW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue72.48M88.6M130.19M199.61M272.3M
Cost of Revenue18.21M25.38M39.64M49.25M67.93M
Gross Profit54.26M63.21M90.55M150.37M204.37M
Gross Margin74.9%71.3%69.6%75.3%75.1%
Research & Development11.08M3.05M6.65M12.23M12.85M
Selling, General & Admin39.82M000152.91M
Operating Expenses52.65M61.29M90.12M141.55M165.76M
Depreciation & Amortization1.74M2.83M11.14M13.05M18.91M
EBITDA5.1M(3.94M)11.95M22.13M41.36M
EBITDA Margin7.0%-4.4%9.2%11.1%15.2%
Operating Income1.61M1.92M431K8.82M38.61M
Operating Margin2.2%2.2%0.3%4.4%14.2%
Interest Income00000
Interest Expense5.44M7.24M21.32M22.79M24.18M
Other Income / Expenses(19.49M)(15.93M)(24.14M)(26.14M)(40.33M)
Income Before Tax(17.87M)(14.01M)(23.71M)(17.32M)(1.72M)
Pre-Tax Margin-24.7%-15.8%-18.2%-8.7%-0.6%
Income Tax Expense133K75K701K161K3.42M
Net Income(18.01M)(14.09M)(24.41M)(17.48M)(5.14M)
Net Margin-24.8%-15.9%-18.7%-8.8%-1.9%
EPS (Basic)(0.69)(0.51)(0.75)(0.49)(0.14)
EPS (Diluted)(0.69)(0.51)(0.75)(0.49)(0.14)
Weighted Avg Shares26.76M27.46M32.62M35.65M36.76M
Weighted Avg Shares (Diluted)26.76M27.46M32.62M35.65M36.76M

Harrow Health, Inc.

NASDAQ:HROW

Intrinsic Alpha fair value

Locked

Current Price

$32.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.